Vestibular schwannomas (VSs) represent Schwann cell (SC) tumors of the vestibular nerve, compromising 10% of all intracranial neoplasms1-3. VSs occur in either sporadic or familial (neurofibromatosis type 2, NF2) forms, both associated with inactivating defects in the NF2 tumor suppressor gene. Treatment for VSs is generally surgical resection or radiosurgery, however the morbidity of such procedures includes deafness, facial neuropathies, spinal fluid leak, imbalance, and tumor regrowth1. Additionally not all patients are acceptable surgical or radiation candidates. Such significant morbidity as well as a lack of alternative therapies has driven investigation into the unique molecular biology of VSs in hopes of developing novel treatments3,4.
Cell culture allows for rapid, facile, and in-depth analysis of molecular and cellular behavior and screening of potential therapeutic compounds. Historically, lack of access to fresh tissue specimens and the fact that schwannoma cells are not immortalized have significantly hampered the use of primary cultures for investigation of schwannoma tumorigenesis. To overcome the limited supply of primary cultures, the immortalized HEI193 VS cell line was generated by transduction with HPV E6 and E7 oncogenes5. This oncogenic transduction introduced significant molecular and phenotypic alterations to the cells, which limit their use as a model for human schwannoma tumors. SC cultures derived from transgenic mouse lines that lack a functional NF2 gene represent another alternative to investigate NF2-dependent SC tumorigenesis in vitro. These cultures however fail to recapitulate the heterogeneous nature of human VSs or account for human specific behavior. Most previous VS culture techniques required relatively long processing times and complicated selective culture techniques6-8. Here we present a simple, reproducible protocol for primary VS cell culture with complete processing in under 3 hr, with 95% tumor cell purity as determined by immunostaining.